For laboratory research education only. Peptides Exchange materials are intended strictly for in-vitro research by qualified professionals. Not for human or animal use or consumption. This guide does not provide dosing, administration, or treatment advice.
Publisher disclosure: Peptides Exchange sells research materials, including ipamorelin. Product links below identify our own listings; they are not independent endorsements or evidence of a particular lot’s quality.
Ipamorelin peptide is a synthetic five-residue peptide studied in growth hormone secretagogue receptor research. For a laboratory evaluating this material, the first questions are practical: Is the molecular identity documented? Does the certificate of analysis match the received lot? Are purity, peptide content, and storage conditions clearly distinguished?
This guide explains the structural identifiers, analytical evidence, and handling records that help answer those questions. Researchers can consult the Peptides Exchange ipamorelin product listing alongside the certificates of analysis page. Request clarification whenever the documentation does not resolve the specific material being supplied.
What is ipamorelin peptide?
Ipamorelin appears in the scientific literature as a growth hormone secretagogue. The foundational paper by Raun and colleagues described its development and pharmacological characterization in experimental systems. The word “selective” in that research describes findings under the study’s conditions; it does not establish that a commercial research material is safe for personal use. [1]
Its research classification also should not be confused with the identity of other peptides discussed in the same field. For broader context, see CJC-1295 vs Ipamorelin vs Sermorelin: How GH Secretagogues Compare.
Ipamorelin structure and chemical identifiers
The parent molecule has the formula C38H49N9O5. Its identity includes the residue sequence, stereochemistry, and terminal modification—not simply the name on a vial. PubChem provides a useful independent reference record. [2]
| Identity field | Reference description |
|---|---|
| Peptide length | Five amino-acid residues: a pentapeptide |
| Sequence | H–Aib–His–D-2-Nal–D-Phe–Lys–NH₂ |
| Aib | 2-Aminoisobutyric acid, a non-proteinogenic amino acid |
| D-2-Nal | D-2-Naphthylalanine |
| D-Phe | D-Phenylalanine |
| C-terminus | Amidated, represented by –NH₂ |
| Parent-molecule molecular weight | Approximately 711.85 g/mol |
| Parent/free-base CAS number | 170851-70-4 |
These identifiers are consistent with the FDA’s 2024 ipamorelin briefing document. They describe the parent molecule and should not automatically be treated as the composition of every salt-containing powder. [3]
Ipamorelin versus ipamorelin acetate
Free-base and acetate descriptions are not interchangeable specifications. An acetate preparation includes associated acetate, and the amount of counterion matters when interpreting a reported mass. FDA’s chemistry review identified inconsistencies between names, formulas, and molecular weights in submitted documents—an example of why matching all identity fields matters. [3]
Before accepting a lot, ask the supplier to identify its chemical form and explain whether the stated quantity represents peptide-equivalent content, salt mass, or another defined basis. Do not resolve conflicting paperwork by choosing whichever number makes the calculation convenient.
Purity, identity, and content answer different questions
A purity percentage is not a complete characterization package. Bachem’s analytical guidance separates molecular identity, chromatographic purity, and product content. These measurements have different purposes. [4]
| Measurement | What it can support | What it does not establish by itself |
|---|---|---|
| Analytical HPLC | The relative chromatographic purity under the stated method | Correct molecular identity, total peptide quantity, or sterility |
| Mass spectrometry / LC-MS | Mass evidence consistent with the expected molecule | Every aspect of sequence and stereochemistry from a matching intact mass alone |
| Peptide-content assay | The amount or fraction of peptide on a defined analytical basis | A complete impurity profile |
| Water and counterion testing | Contributions to sample mass beyond the parent peptide | Biological suitability for every assay |
For example, a report stating “99% HPLC purity” should not be interpreted as proof that 99% of the entire powder mass is the target peptide. Moisture and counterions may require separate measurements. Request the method and reporting basis rather than treating a percentage as a universal quality score. [4]
A practical ipamorelin COA review checklist
A certificate should describe the actual batch, not merely a representative product. Bachem’s analytical FAQ explains the batch-specific role of analytical data sheets and the types of information they may contain. [5] Use the following acceptance questions:
- Traceability: Does the lot identifier match the container and order records?
- Identity: Do the name, sequence, chemical form, formula, and reported mass agree?
- Testing: Are methods, results, dates, and the issuing laboratory identifiable?
- Purity: Is the chromatographic method stated, with a chromatogram available for review?
- Quantity: Is peptide content measured, or is only a nominal fill quantity listed?
- Handling: Are storage conditions and any supported expiry or retest period documented?
- Exceptions: Has the supplier resolved missing or contradictory information in writing?
This is a proposed review workflow, not a claim that every listing supplies every test. For a broader purchasing framework, use our Research Peptide Supplier Evaluation Checklist.
Laboratory handling and storage
Follow the specific lot documentation, safety data sheet, and your laboratory’s approved procedures. General peptide guidance is useful background, but it does not validate an ipamorelin lot’s shelf life.
For dry material, protect the container from moisture and unnecessary exposure. Bachem recommends allowing a cold, sealed container to reach ambient temperature under dry conditions before opening, because condensation can introduce water. Reseal promptly after handling. Use the protective equipment and containment required by the laboratory’s chemical risk assessment. [6]
For laboratory solutions, select conditions supported by the supplier’s analytical documentation and compatible with the intended assay. Solubility depends on chemical properties, including residue composition and terminal groups. A solvent that dissolves the material may still interfere with a cell-based assay. Bachem recommends consulting lot-specific solubility information and evaluating alternatives on a small sample where appropriate. [7]
A useful handling log records receipt date, lot number, storage location, temperature excursions, opening dates, solution preparation details, and any observed change. Define acceptance criteria before experiments begin. Do not assign a universal “good for 30 days” period without supporting stability evidence.
Research-use boundaries and regulatory context
FDA’s safety-risk information identifies concerns with ipamorelin acetate, including potential immunogenicity associated with aggregation and peptide-related impurities, and limited safety information for certain routes of administration. Its scientific history does not establish that retail research preparations are suitable for human use. [8]
A research-use statement is not a blanket legal exemption. Under the intended-use framework in 21 CFR 201.128, claims, advertising, statements, and distribution circumstances can be relevant. This guide addresses laboratory characterization and documentation; it does not authorize clinical use or establish the legal status of a particular sale. [9]
Frequently asked questions
Does a white powder confirm ipamorelin identity?
No. Appearance is an observation, not an identity test. Evaluate the lot’s analytical evidence and consistency with the expected compound. [4]
Can a product page replace a lot-specific COA?
No. A listing describes an offering; a lot-specific report documents testing of a particular batch. Start with the ipamorelin listing, then reconcile its specifications with the documentation supplied for the material you receive.
Is ipamorelin the same as a CJC-1295/ipamorelin blend?
No. A single-compound preparation and a blend require different identity and composition checks. For naming issues involving the other component, see Why “CJC-1295” on a label is not enough.
References and further reading
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139:552–561. DOI: 10.1530/eje.0.1390552.
- PubChem: Ipamorelin, CID 9831659.
- FDA. Ipamorelin-related bulk drug substances: October 29, 2024 PCAC briefing document.
- Bachem. Quality Control of Amino Acids & Peptides: A Guide.
- Bachem. Frequently Asked Questions: analytical data and peptide documentation.
- Bachem. Handling and Storage Guidelines for Peptides.
- Bachem. Peptide Solubility.
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.
- 21 CFR § 201.128: Meaning of “intended uses,” reproduced by Cornell Legal Information Institute.
Leave a Reply